This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Feasibility and Safety of NeuroFlo in Stroke Patients Receiving Tissue Plasminogen Activator (FASTFlo tPA)

This study has been completed.
Information provided by:
CoAxia Identifier:
First received: November 2, 2009
Last updated: March 10, 2010
Last verified: March 2010
To assess the safety and feasibility of using the NeuroFlo catheter to treat acute ischemic stroke patients following administration of intravenous tPA.

Condition Intervention Phase
Ischemic Stroke Device: NeuroFlo catheter Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility and Safety of NeuroFlo in Stroke Patients Receiving tPA

Further study details as provided by CoAxia:

Primary Outcome Measures:
  • An assessment of serious adverse events occurring in ischemic stroke patients undergoing NeuroFlo treatment. [ Time Frame: Baseline to 30 days post-treatment ]

Secondary Outcome Measures:
  • Potential patient benefit will be assessed through collection of neurological indices. [ Time Frame: Baseline through 90 days ]

Enrollment: 22
Study Start Date: May 2007
Study Completion Date: January 2010
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NeuroFlo Treatment Device: NeuroFlo catheter
NeuroFlo™ catheter 45 minute treatment


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ischemic stroke
  • NIHSS between 5-22
  • Persistent clinical deficits following administration of rt-PA

Exclusion Criteria:

  • Planned thrombectomy
  • Aortic pathology
  • Severe heart disease
  • Other conditions the doctor will assess
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01006993

Canada, Alberta
University of Alberta
Edmonton, Alberta, Canada, T6G 2B7
Canada, Ontario
University of Western Ontario
London, Ontario, Canada, N6A 5A5
Trillium Health Centre
Mississauga, Ontario, Canada, L5B 4A2
University of Erlangen
Erlangen, Germany, 91054
Sponsors and Collaborators
Study Director: FASTFlo Steering Committee Various
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Lori Austin, CoAxia, Inc. Identifier: NCT01006993     History of Changes
Other Study ID Numbers: CD-0258
Study First Received: November 2, 2009
Last Updated: March 10, 2010

Additional relevant MeSH terms:
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Tissue Plasminogen Activator
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017